In this study, we utilized multiple omics to validate that EZH2 can modulate endogenous cholesterol synthesis and that blocking the endogenous cholesterol synthesis with SQLE inhibitors can largely enhance the sensitivity of HNSCC cells to EZH2 inhibitors. The gene discussed is EZH2; the disease is head and neck squamous cell carcinoma.